In spite of this tremendous progress made in IBD therapy in recent years, approximately 30% of patients are primarily unresponsive to anti-TNF-α treatment and even among responders, up to 10% lose their response to the drug every year [40]. Here, TNF is linked to inflammatory bowel disease.